



**FOR IMMEDIATE RELEASE**

**Contact:** Kelly Mooney  
VetBiotek  
888.798.2030 x. 103 (office)  
[KMooney@vetbiotek.com](mailto:KMooney@vetbiotek.com)

**VETBIOTEK ANNOUNCES EXTENSION OF LICENSE AGREEMENT FOR  
MICROSILVER BG™**

Innovative Veterinary Dermatological Technology licensed from Bio-Gate AG

**TAMPA, Fla. (August 5, 2016)** – Largo-based VetBiotek, Inc. announced today they have signed a four-year extension to its License Agreement with Bio-Gate AG through December 2022. The License Agreement grants VetBiotek the usage rights and the know-how for developing, marketing and selling products featuring MicroSilver BG™, a silver powder made up of micronized particles of pure medical grade silver, from German company Bio-Gate AG for use in the veterinary channel. The products developed by VetBiotek are used for dermatological applications associated with companion animals and equine. The rights granted to VetBiotek are exclusive in the United States and Canada and non-exclusive elsewhere.

“Since the launch of our MicroSilver BG™ range of products, we have seen the significant value this novel ingredient brings to the veterinary industry to help manage skin and ear conditions of pets,” stated Thomas L. Bell, President of VetBiotek. “In 2015, VetBiotek’s Scientific Advisory Board, consisting of industry leading Veterinary Dermatologists, completed an *in-vitro* scientific study documenting the efficacy of MicroSilver BG™ in eradicating the biofilms of *Staphylococcus pseudintermedius* and *Pseudomonas aeruginosa*, which are common pathogens in canine bacterial infections. This scientific study was presented at the World Congress of Veterinary Dermatology in June of this year. In addition, numerous studies have been completed by Bio-Gate AG that document the proven Antimicrobial spectrum of MicroSilver BG™ against many species of bacteria including Multidrug Resistant Bacteria (e.g., MRSA & MRSP).”

“We are very pleased with our partnership with VetBiotek and the progress that we have made in the veterinary market over the past year,” said Karl Richter, CEO of Bio Gate AG. “We look forward to extending the joint commitment between our two organizations and working together towards the long-term success of both companies. This strategic alliance will help us to continue to develop and launch novel and highly effective products over the years to come and will provide veterinarians with enhanced products to address the needs of their patients.”



**About VetBiotek** – VetBiotek, Inc. is a privately held company that specializes in developing, manufacturing and marketing dermatological and nutritional supplement products for the companion animal and equine market. VetBiotek’s mission is to continually bring innovative solutions to the veterinary marketplace through research and development that will assist veterinarians in their management of disease states. VetBiotek sells its products exclusively to licensed veterinarians through a very select distribution network. VetBiotek is located in Largo, Fla. For more information, please visit [www.vetbiotek.com](http://www.vetbiotek.com).

**About Bio-Gate AG** – The medical technology company Bio-Gate AG develops and markets applications which use unique silver technologies to help prevent infections and thus to improve health. Bio-Gate AG’s specialty is using pure silver to treat materials and surfaces that are used in all areas of daily life – thus providing long-term and medically effective protection against bacteria, microorganisms and other pathogens. Bio-Gate AG works in three fields to supply a variety of products that provide antimicrobial protection: material enhancements, surface coating and testing the antimicrobial or anti-adhesive properties of materials. The Nuremberg-based company offers systems that stretch across the entire value-adding chain, from development to approval in production. For more information, please visit [www.bio-gate.de](http://www.bio-gate.de).